Ultrasound alone detects 92% of breast cancers recalled on DBT exams

Noncalcified lesions observed on digital breast tomosynthesis exams signal that additional imaging is necessary to rule out malignancy. But rather than obtaining additional mammographic views, research suggests using ultrasound alone may be sufficient.

The American Journal of Roentgenology recently published a study that dives deeper into the ultrasound versus mammography discussion. For the research, doctors examined 430 recalled noncalcified lesions in 399 women to determine whether ultrasound alone is a suitable recall tool compared to incorporating ultrasound in conjunction with additional mammographic views. 

“We hypothesized that omitting diagnostic mammography for the evaluation of recalled noncalcified abnormalities from screening DBT might help greatly reduce non-additive diagnostic mammography without missing cancers,” corresponding author, Jessica H. Porembka, MD, with the Department of Radiology at the University of Texas Southwestern Medical Center, and co-authors explained.

Ultrasound alone was performed on 306 lesions, while it was used in addition to mammography for 124 lesions. Needle biopsy was performed on 93 lesions, 38 of which were found to be invasive cancers. Ultrasound alone detected 92% of the cancers (35 out of 38). The other three were discovered using US and additional mammographic views

“Performing US first in the evaluation of noncalcified masses recalled on screening DBT can help reduce the number of women receiving non-additive diagnostic mammography,” the doctors noted. “Because noncalcified lesions make up a large number of recalled lesions, downstream omission of radiation exposure could be significant.” 

Although the results of the study suggest that ultrasound alone is sufficient for recall imaging of most noncalcified lesions, the authors caution that not all lesions are created equal. Some findings, like asymmetries, may require diagnostic mammography, while architectural distortion is best visualized with both ultrasound and mammography combined, or even with contrast-enhanced MRI. 

You can view the detailed research in the American Journal of Roentgenology


Related Breast Imaging Technology Content:

DBT plus synthesized mammography drops patients’ dosage without losing imaging quality

3D mammography approaching 50% of breast imaging systems in the US

Breast MRI screening cuts cancer mortality rates in half for women with lesser-known gene mutations

DBT spot compression views increase reader accuracy

Digital breast tomosynthesis outperforms DM at detecting malignancy in developing asymmetries

AI drops DBT workloads for radiologists by 40% while also reducing recalls

Less experienced radiologists are more susceptible to fatigue when reading DBT exams

Stand-alone AI can reduce radiologists’ screening mammography workloads by 90%

Imaging center has credentials revoked following ‘severe’ issues with mammography screening

Q&A: Should COVID vaccinated patients delay getting breast imaging — new study says no 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

Trimed Popup
Trimed Popup